NCT01953367View on ClinicalTrials.gov

Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Cystic Fibrosis

Interventions

DRUG

Vantobra (tobramycin)

Inhalation

DRUG

TOBI (tobramycin)

Inhalation

Trial Locations (1)

82131

Inamed GmbH, Gauting

Sponsors

Lead Sponsor

Pari Pharma GmbH

All Listed Sponsors

lead

Pari Pharma GmbH

INDUSTRY

NCT01953367 - Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects | Biotech Hunter | Biotech Hunter